- Fee assured
- Verified this account
- Upper GI
Professor Middleton trained at the Universities of Cambridge and Oxford, qualifying in 1991. He trained in Medical Oncology at the Christie Hospital and Paterson Institute in Manchester. He has an international reputation for the care of patients with melanoma, contributing to numerous clinical trials and contributing to the development of new medicines such as vemurafenib, ipilimumab and nivolumab. Prof Middleton is based at Oxford University Hospitals NHS Trust where he also works on the Early Phase Clinical Trials Unit
Areas of interest
Treatment of melanoma and upper GI cancer, including with targeted agents, chemotherapy and immunotherapy. Cancer drug development and experimental therapeutics.
Current NHS consultant posts held
Consultant Medical Oncologist, Oxford University Hospitals NHS Trust.
Melanoma and upper GI cancer therapeutics and translational research. Focus on novel immunotherapies, strategies to modulate DNA damage processing and monitoring the biological effects of treatment.
Early drug development including phase 0 and 1 trials.
Science Translational Medicine, Journal of Clinical Oncology, Cancer Cell, Lancet Oncology, Nature Communications, Cancer Research, Annals of Oncology.
- BA University of Cambridge 1988
- BM BCh University of Oxford 1991
- MRCP Royal College of Physicians of Edinburgh 1994
- PhD University of Manchester 2000
Reference number 3555390
Professional bodies (positions held - last 3 yrs)
- Executive Member International Melanoma Working Group 2007
Affiliations / memberships
American Association of Cancer Research
American Society of Clinical Oncology
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
01865 572192 or out of hours 01865 741841 and ask for the Oncology Ward